These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10377723)

  • 21. Burning mouth syndrome responsive to pramipexol.
    Stuginski-Barbosa J; Rodrigues GG; Bigal ME; Speciali JG
    J Headache Pain; 2008 Feb; 9(1):43-5. PubMed ID: 18219443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine agonists in early therapy for Parkinson disease: promise and problems.
    Tanner CM
    JAMA; 2000 Oct; 284(15):1971-3. PubMed ID: 11035895
    [No Abstract]   [Full Text] [Related]  

  • 23. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
    Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
    Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A; Lang AE; Shapiro CM
    Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
    Fedorova NV; Chigir' IP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(6):26-33. PubMed ID: 16841480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pramipexole in the treatment of advanced Parkinson's disease.
    Möller JC; Oertel WH
    Eur J Neurol; 2000 May; 7 Suppl 1():21-5. PubMed ID: 11054155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rhabdomyolysis as a complication of Parkinson's disease].
    Pozzoni P; Tentori F; Corti M; Pozzi C
    G Ital Nefrol; 2002; 19(1):13-7. PubMed ID: 12165940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Pan T; Le W; Jankovic J
    Neurology; 2004 Jan; 62(2):343; author reply 343-4. PubMed ID: 14750218
    [No Abstract]   [Full Text] [Related]  

  • 31. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?
    Goetz CG; Blasucci L; Stebbins GT
    Neurology; 1999 Apr; 52(6):1227-9. PubMed ID: 10214748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ropinirol: a new dopamine agonist in the treatment of Parkinson's disease].
    Giménez-Roldán S
    Neurologia; 1997 Oct; 12(8):354-61. PubMed ID: 9471165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction: pramipexole: a novel dopamine agonist for the treatment of Parkinson's disease.
    de Yebenes JG
    Eur J Neurol; 2000 May; 7 Suppl 1():1-2. PubMed ID: 11054151
    [No Abstract]   [Full Text] [Related]  

  • 34. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
    Nissen T; Newman EJ; Grosset KA; Daghem M; Pal G; Stewart M; Odin P; Macphee GJ; Grosset DG
    Scott Med J; 2012 Nov; 57(4):217-20. PubMed ID: 23002158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 38. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dopamine agonists in the treatment of motor complications in advanced Parkinson's disease].
    Sławek J
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S29-33. PubMed ID: 17941456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.